(Q42230787)

19 October 2017

Effect of IL-6 on the insulin sensitivity in patients with type 2 diabetes (English)

1 reference

19 October 2017

1 reference

1 reference

3

1 reference

19 October 2017

P Plomgaard

4

0 references

Bente Klarlund Pedersen

6

object named as

B K Pedersen

1 reference

19 October 2017

N M Harder-Lauridsen

1

1 reference

19 October 2017

R Krogh-Madsen

2

1 reference

19 October 2017

L Leick

5

1 reference

19 October 2017

C P Fischer

7

1 reference

19 October 2017

28 January 2014

1 reference

American Journal of Physiology - Endocrinology and Metabolism

19 October 2017

1 reference

19 October 2017

306

1 reference

19 October 2017

7

1 reference

19 October 2017

E769-78

1 reference

"Sick fat," metabolic disease, and atherosclerosis

19 October 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Computational reconstruction of the human skeletal muscle secretome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Physiological concentrations of interleukin-6 directly promote insulin secretion, signal transduction, nitric oxide release, and redox status in a clonal pancreatic β-cell line and mouse islets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Interleukin-6 autoantibodies are involved in the pathogenesis of a subset of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Anti-interleukin-6 antibodies in normal human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Interleukin-6 promotes myogenic differentiation of mouse skeletal muscle cells: role of the STAT3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Altered response of skeletal muscle to IL-6 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Metabolic responses to reduced daily steps in healthy nonexercising men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

An enzymic method for measurement of glycogen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

The diseasome of physical inactivity--and the role of myokines in muscle--fat cross talk

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Satellite cells derived from obese humans with type 2 diabetes and differentiated into myocytes in vitro exhibit abnormal response to IL-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Dose-dependent effects of recombinant human interleukin-6 on glucose regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Interleukin-6 markedly decreases skeletal muscle protein turnover and increases nonmuscle amino acid utilization in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Interleukin-6 stimulates lipolysis and fat oxidation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

IL-6 selectively stimulates fat metabolism in human skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Comparative proteomic analysis of the insulin-induced L6 myotube secretome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

Interleukin-6 Directly Increases Glucose Metabolism in Resting Human Skeletal Muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00571.2013

10.1152/AJPENDO.00571.2013

21 January 2018

Identifiers

DOI

1 reference

19 October 2017

1 reference